PMID- 31953463
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20240328
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jan 17
TI  - Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with 
      solvent-based taxanes for metastatic breast cancer: A meta-analysis.
PG  - 530
LID - 10.1038/s41598-019-57380-0 [doi]
LID - 530
AB  - The curative effects of nanoparticle albumin-bound (nab)-paclitaxel in the 
      first-line treatment of metastatic breast cancer (MBC) are still controversial, 
      with even more after the removal of marketing approval of indication of 
      bevacizumab. Five electronic databases and the related resources were searched 
      for eligible randomized clinical trials (RCTs) without year and language 
      restrictions to perform a meta-analysis. The studies were comparing the efficacy 
      and safety between nab-paclitaxel chemotherapy versus solvent-based (sb)-taxanes 
      chemotherapy such as sb-paclitaxel and docetaxel. The primary end points were 
      overall response rate (ORR) and disease control rate (DCR). Secondary end points 
      were progression-free survival (PFS), overall survival (OS), adverse events 
      (AEs), and dose discontinuation rate (DDR). Five RCTs (1,554 patients) were 
      finally identified from 1,902 studies. When compared to sb-paclitaxel, 
      nab-paclitaxel showed significant beneficial effects in terms of ORR (OR 2.39, 
      95% CI 1.69-3.37, p < 0.001), DCR (OR 1.89, 95% CI 1.07-3.35, p = 0.03), and PFS 
      (HR 0.75, 95% CI 0.62-0.90, p = 0.002). Nab-paclitaxel also showed significantly 
      longer OS (HR 0.73, 95% CI 0.54-0.99, p = 0.04) than docetaxel. AEs and DDR were 
      comparable between the two arms. Using nab-paclitaxel could significantly improve 
      efficacy with comparable toxicities in the treatment of MBC.
FAU - Lee, Hwaryeon
AU  - Lee H
AD  - Graduate School of Converging Clinical & Public Health, Ewha Womans University, 
      Seoul, 03760, Republic of Korea.
AD  - Department of Pharmacy, Ewha Womans University Mokdong Hospital, Seoul, 07985, 
      Republic of Korea.
FAU - Park, Sohyun
AU  - Park S
AD  - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, 
      Republic of Korea.
FAU - Kang, Ji Eun
AU  - Kang JE
AD  - College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea.
AD  - Department of Pharmacy, National Medical Center, Seoul, 04564, Republic of Korea.
FAU - Lee, Hee Min
AU  - Lee HM
AD  - Division of Life & Pharmaceutical Science, Ewha Womans University, Seoul, 03760, 
      Republic of Korea.
AD  - Department of Pharmacy, Ewha Womans University Seoul Hospital, Seoul, 07985, 
      Republic of Korea.
FAU - Kim, Sun Ah
AU  - Kim SA
AD  - Department of Pharmacy, Ewha Womans University Mokdong Hospital, Seoul, 07985, 
      Republic of Korea.
AD  - College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea.
FAU - Rhie, Sandy Jeong
AU  - Rhie SJ
AUID- ORCID: 0000-0003-2554-3370
AD  - Graduate School of Converging Clinical & Public Health, Ewha Womans University, 
      Seoul, 03760, Republic of Korea. sandy.rhie@ewha.ac.kr.
AD  - Department of Pharmacy, Ewha Womans University Mokdong Hospital, Seoul, 07985, 
      Republic of Korea. sandy.rhie@ewha.ac.kr.
AD  - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, 
      Republic of Korea. sandy.rhie@ewha.ac.kr.
AD  - College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea. 
      sandy.rhie@ewha.ac.kr.
AD  - Division of Life & Pharmaceutical Science, Ewha Womans University, Seoul, 03760, 
      Republic of Korea. sandy.rhie@ewha.ac.kr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20200117
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Albumin-Bound Paclitaxel)
RN  - 0 (Solvents)
RN  - 0 (Taxoids)
SB  - IM
MH  - Albumin-Bound Paclitaxel/adverse effects/*pharmacology/therapeutic use
MH  - Breast Neoplasms/*drug therapy/*pathology
MH  - Humans
MH  - Neoplasm Metastasis
MH  - *Safety
MH  - Solvents/*chemistry
MH  - Taxoids/adverse effects/*chemistry/*pharmacology/therapeutic use
PMC - PMC6969039
COIS- The authors declare no competing interests.
EDAT- 2020/01/19 06:00
MHDA- 2020/11/12 06:00
PMCR- 2020/01/17
CRDT- 2020/01/19 06:00
PHST- 2019/03/29 00:00 [received]
PHST- 2019/12/30 00:00 [accepted]
PHST- 2020/01/19 06:00 [entrez]
PHST- 2020/01/19 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
PHST- 2020/01/17 00:00 [pmc-release]
AID - 10.1038/s41598-019-57380-0 [pii]
AID - 57380 [pii]
AID - 10.1038/s41598-019-57380-0 [doi]
PST - epublish
SO  - Sci Rep. 2020 Jan 17;10(1):530. doi: 10.1038/s41598-019-57380-0.